Global Diverticulitis Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Diverticulitis Market Size

• The global diverticulitis market size was valued at USD 1.95 billion in 2025 and is expected to reach USD 3.60 billion by 2033, at a CAGR of 8.00% during the forecast period
• The market growth is largely driven by the rising prevalence of gastrointestinal disorders, increasing awareness about digestive health, and the expansion of advanced diagnostic and therapeutic options for diverticulitis
• Furthermore, growing patient preference for minimally invasive treatments, along with the development of innovative drugs and interventions, is positioning diverticulitis management as a critical component of gastrointestinal care. These combined factors are accelerating the adoption of advanced therapies and interventions, thereby significantly boosting the industry's growth

Diverticulitis Market Analysis

• Diverticulitis, a gastrointestinal condition characterized by inflammation or infection of diverticula in the colon, is increasingly recognized as a critical area of focus in digestive health management due to its prevalence, potential complications, and the rising demand for effective treatment options in both outpatient and hospital settings
• The escalating demand for diverticulitis management solutions is primarily driven by the growing incidence of gastrointestinal disorders, increased patient awareness about digestive health, and a rising preference for minimally invasive treatments and targeted therapeutic interventions
• North America dominated the diverticulitis market with the largest revenue share of 38.7% in 2025, attributed to high prevalence rates, advanced healthcare infrastructure, early adoption of innovative surgical and pharmaceutical treatments, and a strong presence of key industry players developing novel therapies and diagnostic tools
• Asia-Pacific is expected to be the fastest-growing region in the diverticulitis market during the forecast period due to increasing urbanization, changing dietary habits, rising healthcare awareness, and expanding access to advanced medical facilities
• Complicated segment dominated the market with a share of 42.5% in 2025, driven by the rising prevalence of severe cases requiring advanced medical intervention, including hospitalization, imaging diagnostics, and surgical or targeted pharmacological treatment

Report Scope and Diverticulitis Market Segmentation

Diverticulitis Market Trends

“Advancements in Minimally Invasive and Targeted Therapies”

• A significant and accelerating trend in the global diverticulitis market is the growing adoption of minimally invasive surgical techniques and targeted pharmacological therapies, which are enhancing patient recovery and reducing hospitalization time
• For instance, laparoscopic sigmoidectomy procedures are increasingly preferred over traditional open surgery, offering reduced post-operative pain and faster return to normal activities. Similarly, targeted biologic therapies such as monoclonal antibodies are emerging for complicated diverticulitis cases
• Integration of advanced imaging and AI-assisted diagnostics enables early detection of complications such as abscesses or perforation, allowing personalized treatment planning and improved clinical outcomes. For instance, some hospitals are using AI algorithms to predict recurrence risk and optimize antibiotic regimens
• Telemedicine and remote patient monitoring are being adopted to manage post-treatment care, ensuring adherence to therapy and timely identification of flare-ups, thereby reducing readmissions
• This trend towards more precise, patient-centric, and technology-assisted management is reshaping expectations for diverticulitis care. Consequently, healthcare providers are investing in AI-enabled diagnostic tools and minimally invasive treatment solutions to improve patient experience and outcomes
• The demand for innovative therapies that shorten recovery time, reduce complications, and integrate digital health monitoring is growing rapidly across both hospital and outpatient care settings
• Hospitals and specialty clinics are adopting integrated care pathways that combine diet, lifestyle counseling, and pharmacological intervention to improve long-term patient outcomes

Diverticulitis Market Dynamics

Driver

“Rising Prevalence of Gastrointestinal Disorders and Patient Awareness”

• The increasing prevalence of diverticulitis and related gastrointestinal disorders, coupled with growing patient awareness about digestive health, is a significant driver for the rising demand for advanced treatments and interventions
• For instance, in March 2025, AbbVie Inc. launched initiatives to expand access to biologics for complicated diverticulitis patients, aiming to improve clinical outcomes and patient adherence
• As awareness of early intervention benefits grows, patients are seeking minimally invasive and targeted therapies that reduce hospitalization and recurrence rates, creating higher adoption of advanced solutions
• Furthermore, the expanding healthcare infrastructure and greater accessibility to diagnostic imaging and specialist care are enabling timely treatment and effective disease management
• The increasing demand for personalized treatment plans, coupled with the growing emphasis on preventive care and lifestyle management, is further propelling the adoption of advanced therapeutic and monitoring solutions
• Rising investment in R&D by pharmaceutical and medtech companies to develop novel therapeutics and surgical tools for diverticulitis is creating additional growth opportunities
• Growing collaborations between hospitals and digital health companies for remote monitoring and teleconsultation services are increasing patient engagement and improving post-treatment adherence

Restraint/Challenge

“Limited Access to Advanced Care and High Treatment Costs”

• Geographic disparities in healthcare infrastructure and access to advanced surgical or pharmacological therapies pose a significant challenge to the broader market adoption of diverticulitis treatment
• For instance, patients in rural or underserved regions may not have access to minimally invasive procedures or biologic therapies, limiting treatment options and outcomes
• High costs associated with advanced pharmacological regimens, surgical interventions, and hospitalization can deter adoption among price-sensitive patients, particularly in developing countries
• Insurance coverage limitations and lack of reimbursement for novel therapies further hinder accessibility, creating adoption barriers despite clinical efficacy
• Overcoming these challenges requires increased investment in healthcare infrastructure, affordable pricing strategies, and expansion of insurance coverage for advanced diverticulitis management
• Variability in clinical guidelines and physician familiarity with emerging therapies can slow adoption of innovative treatment protocols across regions
• Concerns about potential side effects of biologics and long-term antibiotic use may reduce patient willingness to opt for advanced therapies without proper education and counseling

Diverticulitis Market Scope

The market is segmented on the basis of type, diagnosis, route of administration, end-users, and distribution channel.

• By Type

On the basis of type, the diverticulitis market is segmented into complicated, uncomplicated, and others. The complicated diverticulitis segment dominated the market with the largest market revenue share of 42.5% in 2025, driven by the rising prevalence of severe cases requiring hospitalization, advanced imaging diagnostics, and surgical or targeted pharmacological treatment. Complicated cases often lead to abscesses, perforation, or peritonitis, which necessitate intensive management, thereby increasing healthcare expenditure. Hospitals and specialty clinics frequently prioritize the management of complicated diverticulitis due to the associated clinical risk and the need for multidisciplinary care. The adoption of minimally invasive surgical techniques and biologic therapies for complicated cases further strengthens the segment’s market dominance. High recurrence risk and complications associated with severe diverticulitis also drive consistent demand for effective interventions. Overall, complicated diverticulitis remains a focal point for both product development and treatment adoption in major healthcare markets.

The uncomplicated diverticulitis segment is expected to witness the fastest growth rate of 9.2% from 2026 to 2033, fueled by increasing awareness of early intervention and preventive care. Uncomplicated cases are often managed with oral antibiotics, dietary modifications, and outpatient monitoring, reducing hospitalization and healthcare costs. Growing patient awareness campaigns and telemedicine adoption allow timely diagnosis and management of mild cases, which supports market growth. Advances in diagnostic tools such as CT imaging and lab tests are enabling physicians to detect uncomplicated diverticulitis earlier. Rising lifestyle-associated gastrointestinal disorders in younger populations contribute to the increasing prevalence of uncomplicated cases. In addition, healthcare providers are increasingly favoring non-invasive treatment protocols to improve patient quality of life and reduce procedure-related risks.

• By Diagnosis

On the basis of diagnosis, the market is segmented into imaging test, blood/urine/stool test, liver test, and others. The imaging test segment dominated the market with the largest revenue share in 2025 due to its critical role in accurately diagnosing diverticulitis, determining severity, and guiding treatment decisions. CT scans, ultrasound, and MRI are routinely used to identify abscesses, perforations, or bowel obstruction, providing physicians with detailed visualization necessary for complicated case management. Hospitals and specialty clinics widely rely on imaging diagnostics to plan interventions, monitor progression, and assess post-treatment recovery. Imaging tests also reduce misdiagnosis risk and help in stratifying patients for surgical or pharmacologic therapy. The increasing availability of advanced imaging technology in urban and semi-urban healthcare centers further strengthens the dominance of this segment.

The blood/urine/stool test segment is expected to witness the fastest CAGR from 2026 to 2033, driven by the increasing adoption of non-invasive diagnostic methods for early detection and monitoring of diverticulitis. These tests help identify infection, inflammation, or bleeding without requiring invasive procedures. Rapid diagnostic kits, home test kits, and automated lab technologies are contributing to growing demand in outpatient settings. Such diagnostics are also integrated into preventive health programs, allowing early detection of recurrent or mild cases. Blood and stool biomarkers are increasingly used for patient monitoring, reducing hospital visits and enabling telemedicine-based follow-up care. The segment’s growth is further supported by rising awareness and accessibility of lab testing in developing regions.

• By Route of Administration

On the basis of route of administration, the diverticulitis market is segmented into oral, parenteral, and others. The oral administration segment dominated the market with the largest revenue share in 2025 due to the wide use of oral antibiotics as the first-line treatment for uncomplicated cases. Oral therapy is convenient for patients, reduces hospitalization, and allows outpatient management, which is especially important in emerging markets. Physicians prefer oral antibiotics for mild diverticulitis to prevent complications and recurrence. Patient compliance and adherence to oral therapy are supported by simplified dosage forms and combination therapies. The growth of homecare services and telemedicine follow-ups reinforces the dominance of oral administration. Oral formulations are also cost-effective compared to parenteral therapies, increasing their adoption in both developed and developing regions.

The parenteral administration segment is expected to witness the fastest growth rate from 2026 to 2033, fueled by the increasing prevalence of complicated diverticulitis cases requiring intravenous antibiotics or biologic therapy. Parenteral therapy is preferred in hospitals and specialty clinics for severe infections, abscesses, or post-operative care. Advances in infusion devices and hospital-based protocols have improved treatment efficiency and patient outcomes. Parenteral treatment also allows precise dosage control and rapid therapeutic response, critical for high-risk patients. Growing healthcare infrastructure and the availability of advanced IV therapies in emerging regions further support market growth.

• By End-Users

On the basis of end-users, the market is segmented into hospitals, homecare, specialty clinics, and others. The hospitals segment dominated the market with the largest revenue share in 2025 due to the high number of complicated diverticulitis cases requiring inpatient care, surgery, and advanced diagnostics. Hospitals offer comprehensive facilities including imaging, ICU support, and multidisciplinary care teams. The presence of advanced diagnostic tools, skilled physicians, and treatment options makes hospitals the primary choice for diverticulitis management. Hospitals also drive market growth through adoption of new surgical techniques, biologic therapies, and integrated care pathways.

The homecare segment is expected to witness the fastest growth rate from 2026 to 2033, fueled by the rising adoption of telemedicine, remote patient monitoring, and outpatient management of uncomplicated diverticulitis cases. Homecare services reduce hospital burden, lower costs, and improve patient comfort. Growth in homecare infrastructure, coupled with oral therapy adoption and wearable monitoring devices, is expanding access to treatment in suburban and rural areas. The shift towards patient-centered care and preventive health programs further drives this segment.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment dominated the market with the largest revenue share in 2025 due to the direct availability of critical medications and biologic therapies for inpatient and emergency treatment of complicated diverticulitis. Hospital pharmacies ensure timely supply for high-risk patients and facilitate integration with hospital protocols. The presence of trained pharmacists and inventory management systems in hospitals enhances adherence to treatment protocols.

The online pharmacy segment is expected to witness the fastest growth rate from 2026 to 2033, driven by increasing patient preference for convenient, home-delivered medications. Online channels allow access to oral therapies, home diagnostic kits, and follow-up prescriptions. Rising smartphone penetration, secure payment systems, and digital healthcare platforms are enabling easier adoption of online pharmacies. This trend is particularly strong in urban regions and emerging economies where patients seek affordable and accessible medication delivery options.

Diverticulitis Market Regional Analysis

• North America dominated the diverticulitis market with the largest revenue share of 38.7% in 2025, attributed to high prevalence rates, advanced healthcare infrastructure, early adoption of innovative surgical and pharmaceutical treatments, and a strong presence of key industry players developing novel therapies and diagnostic tools
• Patients and healthcare providers in the region increasingly value minimally invasive surgical techniques, targeted pharmacological therapies, and integrated post-treatment care for improved outcomes
• This widespread adoption is further supported by well-established hospitals, a technologically advanced medical ecosystem, and growing awareness of preventive digestive health measures, establishing advanced diverticulitis management as a preferred solution for both outpatient and hospital settings

U.S. Diverticulitis Market Insight

The U.S. diverticulitis market captured the largest revenue share of 82% in 2025 within North America, fueled by the high prevalence of gastrointestinal disorders and the widespread adoption of advanced diagnostic and treatment options. Patients and healthcare providers increasingly prioritize minimally invasive surgical procedures and targeted pharmacological therapies to improve recovery and reduce complications. The growing availability of outpatient care, telemedicine services, and integrated post-treatment monitoring is further propelling the diverticulitis market. Moreover, awareness campaigns and preventive health programs are significantly contributing to the early diagnosis and management of diverticulitis.

Europe Diverticulitis Market Insight

The Europe diverticulitis market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by the rising prevalence of gastrointestinal disorders and increasing access to advanced healthcare infrastructure. Urbanization and lifestyle changes are fostering higher incidence rates, prompting the adoption of effective medical and surgical interventions. European patients are increasingly seeking minimally invasive procedures and biologic therapies that reduce hospitalization and improve quality of life. The region is experiencing significant growth across hospital, outpatient, and specialty clinic applications, with integrated care pathways becoming more common.

U.K. Diverticulitis Market Insight

The U.K. diverticulitis market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing patient awareness and the rising demand for advanced treatment options. Growing concerns regarding gastrointestinal health and potential complications are encouraging early intervention through minimally invasive procedures and targeted pharmacotherapy. The U.K.’s advanced healthcare infrastructure, along with robust diagnostic capabilities and strong patient education initiatives, is expected to continue stimulating market growth.

Germany Diverticulitis Market Insight

The Germany diverticulitis market is expected to expand at a considerable CAGR during the forecast period, fueled by the country’s advanced medical infrastructure and increasing focus on gastrointestinal health. Rising patient demand for minimally invasive surgeries, targeted drug therapies, and integrated post-treatment care is driving adoption. Germany’s emphasis on research, clinical innovation, and preventive healthcare promotes the use of advanced interventions, particularly in hospital and specialty clinic settings. Awareness campaigns and strong physician networks further support market growth.

Asia-Pacific Diverticulitis Market Insight

The Asia-Pacific diverticulitis market is poised to grow at the fastest CAGR of 23% during the forecast period of 2026 to 2033, driven by rising incidence of gastrointestinal disorders, increasing healthcare access, and growing awareness about digestive health in countries such as China, Japan, and India. Expansion of hospital infrastructure, telemedicine, and diagnostic capabilities is boosting the adoption of advanced treatment options. Furthermore, government initiatives promoting preventive healthcare and early intervention are facilitating the uptake of minimally invasive procedures and targeted therapies, making effective diverticulitis care increasingly accessible.

Japan Diverticulitis Market Insight

The Japan diverticulitis market is gaining momentum due to the country’s high healthcare standards, advanced diagnostic capabilities, and growing patient awareness. Japanese patients increasingly prefer minimally invasive surgeries and personalized pharmacological treatments for effective management. Integration of digital health tools and post-treatment monitoring is fueling growth. Moreover, the aging population is likely to increase the demand for convenient, safe, and efficient diverticulitis treatment options in both residential and hospital care settings.

India Diverticulitis Market Insight

The India diverticulitis market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to increasing awareness of gastrointestinal health, expanding healthcare infrastructure, and rising patient adoption of advanced therapies. India is witnessing growing demand for minimally invasive surgeries, targeted drug therapies, and outpatient care services. Government initiatives to improve digestive health, rising disposable incomes, and greater accessibility to specialty clinics are key factors propelling the market. In addition, affordable treatment options and expanding telemedicine services are enhancing patient access and driving market growth.

Diverticulitis Market Share

The Diverticulitis industry is primarily led by well-established companies, including:

• Pfizer Inc. (U.S.)
• Johnson & Johnson Services, Inc. (U.S.)
• F. Hoffmann La Roche AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Sanofi (France)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• Abbott (U.S.)
• Takeda Pharmaceutical Company Limited (Japan)
• Eli Lilly and Company (U.S.)
• Amgen Inc. (U.S.)
• Viatris Inc. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Astellas Pharma Inc. (Japan)
• Eisai Co., Ltd. (Japan)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Reddy’s Laboratories Ltd. (India)

What are the Recent Developments in Global Diverticulitis Market?

• In November 2025, researchers published a first‑of‑its‑kind polygenic risk score for diverticulitis, showing that a genetics‑based score is significantly associated with diverticulitis prevalence and severity across diverse populations, potentially enabling improved risk stratification and personalized clinical decision‑making. This work could pave the way for future clinical use of genetic risk profiling to guide elective interventions and disease management strategies in diverticulitis
• In October 2025, a study reported that severe diverticulitis cases are rising sharply among Americans under age 50, with younger patients more likely than older adults to require invasive procedures such as surgery or drainage for complications such as abscesses or perforations. This shift in demographic trends highlights an emerging public health concern and may influence future screening and treatment strategies
• In October 2025, at the Clinical Congress 2025, surgeons discussed new data and ongoing controversies in diverticulitis management, emphasizing individualized treatment plans that balance patient preferences and clinical factors, recognizing that traditional approaches may not suit all patients
• In July 2025, a large observational study debunked the long‑standing diet myth that nuts, seeds, and corn increase diverticulitis risk, finding no link between these foods and diverticulitis diagnosis. Instead, lifestyle patterns such as smoking, obesity, and processed food intake were more strongly associated with risk, reshaping dietary guidance for patients
• In October 2024, experts at a major surgical conference highlighted “new approaches” to diverticulitis management, including debates over elective surgery, microbiome influences, and indications for operative intervention, reflecting a broader shift toward evidence‑based, patient‑specific care pathways

SKU-53665